MedPath

An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423

Completed
Conditions
Hepatocellular Carcinoma
Liver Disease
Registration Number
NCT01316679
Lead Sponsor
Vanderbilt University Medical Center
Brief Summary

Specific urine proteases or groups of these enzymes can be reliable biomarkers and an effective gauge of response to therapy in patients with hepatocellular carcinoma.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
87
Inclusion Criteria
  • Ability and willingness to provide written informed consent
  • Must be between 18-90 years of age at the time of consent
  • Ability to provide urine specimen at protocol-defined timepoints
  • Must have treatment interventions planned that are directly related to liver disease (excluding those assigned to group 3-Controls)
Exclusion Criteria
  • Suspected inability, e.g. unwillingness to comply with study procedures or unwillingness to provide written consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath